20150 WEBCAST: Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options
This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented.
This activity can be accessed using the following URL: www.peerview.com/JHF
This activity has been designed to meet the educational needs of hematologists, oncologists, hematologist-oncologists, bone marrow transplant specialists and nurses, as well as other clinicians involved in the care of patients with multiple myeloma.
Upon completion of this activity, participants should be better able to:
- Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma
- Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma
- Recommend optimized induction and post-ASCT maintenance/ consolidation regimens for eligible patients with multiple myeloma
- Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease
This activity is supported by educational grants from Adaptive Biotechnologies, Amgen, Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Takeda Oncology, and Sanofi Genzyme.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Sagar Lonial MD, FACP Chair and Professor Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amgen; Bristol-Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc.
Philippe Moreau, MD Professor of Clinical Hematology Nantes Faculty of Medicine Head of The Translational Research Program University Hospital of Nantes Nantes, France
Philippe Moreau, MD, has a financial interest/relationship or affiliation in the form of: Other Financial or Material Support for Speaker for AbbVie; Amgen; Celgene Corporation; and Janssen Pharmaceuticals, Inc.
Carmine DeLuca PVI, PeerView Institute for Medical Education Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Providership, Credit, and Support This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.